BC Extra | Nov 23, 2019
Company News

Nov. 22 Company Quick Takes: AZ’s Btk inhibitor gains expanded approval; plus WuXi Vaccines, SK Bio, ViiV, Horizon and Neon

Label expansion for AZ’s Calquence under Project ORBIS  FDA approved an sNDA for Calquence acalabrutinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat chronic lymphocytic leukemia and small lymphocytic leukemia under the agency’s Real-Time Oncology Review...
BC Week In Review | Feb 15, 2019
Company News

Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and in-licensed exclusive European...
BC Extra | Feb 14, 2019
Company News

Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and in-licensed exclusive European...
Items per page:
1 - 3 of 3